Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus.
The effect of ramipril (an angiotensin [AT]-converting enzyme inhibitor), telmisartan (an AT-II type 1 receptor blocker), or their combination on inflammation and lipid peroxidation was assessed in 37 patients with type 2 diabetes who were free of coronary artery disease. All regimens were associated with a significant reduction of C-reactive protein and oxidized low-density lipoprotein cholesterol serum levels (p <0.001). These results further enlighten the mechanisms underlying the cardiovascular beneficial effect of renin-AT system inhibition.
Koulouris
Spyridon
S
First Cardiology Department, Department of Endocrinology, Diabetes and Metabolism and Hematology Laboratory, Evangelismos Hospital, Athens, Greece. skoulouris@ath.forthnet.gr
Symeonides
Phivos
P
Triantafyllou
Konstantinos
K
Ioannidis
Georgios
G
Karabinos
Ilias
I
Katostaras
Theofanis
T
El-Ali
Mahmud
M
Theodoridis
Theodoros
T
Vratsista
Ekaterini
E
Thalassinos
Nikolaos
N
Kokkinou
Vassiliki
V
Nanas
Ioannis
I
Stamatelopoulos
Stamatios
S
Toutouzas
Pavlos
P
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis*; D008078:Cholesterol, LDL / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D017257:Ramipril / Q000627:therapeutic use*; D000077333:Telmisartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D008078:Cholesterol, LDL; D002097:C-Reactive Protein; D017257:Ramipril; D000077333:Telmisartan